BIND Biosciences to Present at AACR 2012 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins^TM, that are capable of up to a ten-fold increase in drug concentration at tumor sites, announced today that a poster presentation on its lead drug candidate BIND-014, has been selected for a late-breaking clinical research presentation at the American Association for Cancer Research (AACR) 2012 Annual Meeting taking place March 31-April 4, 2012 in Chicago, IL. In addition, BIND Biosciences will participate in an NCI/NIH sponsored session on materials characterization for cancer treatment and diagnosis.

Late-Breaking Poster Presentation:

• (Abstract #LB452): Wednesday, April 4, 2012, 8:00 AM - 12:00 PM, “A phase I, open label , safety, pharmacokinetic and pharmacodynamic dose escalation study of BIND-014 given by IV infusion to patients with advanced or metastatic cancer,” Jason Summa, BIND Biosciences, Late-Breaking Poster Session LBPO.CL02, Late-Breaking Research: Clinical Research, McCormick Place West (Hall F), Poster Section 39

NCI/NIH-Sponsored Session:

• (Session NIH11): Tuesday, Apr 3, 2012, 12:00 - 1:30 PM, “The NCI's Nanotechnology Characterization Laboratory: How to Evaluate Novel Materials for Cancer Therapy and Diagnosis,” Jeff Hrkach, Ph.D., BIND Biosciences, NCI/NIH-Sponsored Session, McCormick Place West (Level 1), Room W194

About BIND-014

BIND-014 is a programmable nanomedicine that combines a targeting ligand and a therapeutic nanoparticle. BIND-014 contains docetaxel, a proven cancer drug which is approved in major cancer indications including breast, prostate and lung, encapsulated in FDA-approved biocompatible and biodegradable polymers. BIND-014 is targeted to prostate specific membrane antigen (PSMA), a cell surface antigen abundantly expressed on the surface of cancer cells and on new blood vessels that feed a wide array of solid tumors. In preclinical cancer models, BIND-014 was shown to deliver up to ten-fold more docetaxel to tumors than an equivalent dose of conventional docetaxel. The increased accumulation of docetaxel at the site of disease translated to marked improvements in antitumor activity and tolerability. BIND-014 is currently in Phase 1 human clinical testing in patients with advanced or metastatic solid tumor cancers (NCT01300533). The early development of BIND-014 was funded in part by the National Cancer Institute and the U.S. National Institutes of Standards and Technology (NIST) under its Advanced Technology Program (ATP).

About BIND Biosciences

BIND Biosciences is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins^TM. BIND's Medicinal Nanoengineering^TM platform enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.

BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best-in-class drugs and improve patient outcomes in the areas of oncology, inflammatory diseases and cardiovascular disorders. BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products.

BIND is backed by leading investors, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments, EndeavourVision and Rusnano. BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine, Professors Robert Langer, David H. Koch Institute Professor of the Massachusetts Institute of Technology (MIT) and Omid Farokhzad, Associate Professor of Harvard Medical School. For more information, please visit the company's web site at www.bindbio.com.